Nasdaq · Healthcare
Sunshine Biopharma Inc. (SBFM)
As-reported financials and recent SEC filings for Sunshine Biopharma Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.
Snapshot
Revenue
$36.3M
Net income
$-6.0M
Net margin
-16.5%
Diluted EPS
—
ROE
-25.9%
P/E (TTM)
—
Market cap
—
Debt / equity
—
Income statement (as reported)
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $36.3M | $34.9M | $24.1M | $4.3M | $228,426 |
| Gross profit | $12.3M | $10.7M | $8.3M | $1.7M | $110,596 |
| Operating income | $-6.2M | $-5.8M | $-4.8M | $-27.0M | $-2.4M |
| Net income | $-6.0M | $-5.1M | $-4.5M | $-26.7M | $-12.4M |
| Diluted EPS | — | $-1.22 | $-1.06 | $-6.31 | $-2.85 |
Source: company XBRL financial statements on SEC EDGAR.
Recent SEC filings
DEF 14C2026-06-08
View on EDGAR →PRE 14C2026-05-29
View on EDGAR →8-K2026-05-29
View on EDGAR →SCHEDULE 13G2026-05-22
View on EDGAR →SCHEDULE 13G2026-05-21
View on EDGAR →8-K2026-05-19
View on EDGAR →424B42026-05-19
View on EDGAR →EFFECT2026-05-18
View on EDGAR →Largest Healthcare peers
Go deeper on SBFM
Search Sunshine Biopharma Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.
Start freeOr check your whole portfolio free — no account needed.
Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.